Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 302

1.

A randomised clinical study of alfacalcidol and paricalcitol.

Hansen D.

Dan Med J. 2012 Feb;59(2):B4400.

PMID:
22293059
2.

Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.

Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L.

Nephrol Dial Transplant. 2012 Jun;27(6):2263-9. doi: 10.1093/ndt/gfr668. Epub 2011 Dec 1.

PMID:
22140123
3.
4.

No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial.

Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, Madsen JK, Tougaard BG, Marckmann P, Thye-Roenn P, Nielsen JE, Kreiner S, Brandi L.

Kidney Int. 2011 Oct;80(8):841-50. doi: 10.1038/ki.2011.226. Epub 2011 Aug 10.

6.

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.

J Am Soc Nephrol. 1998 Aug;9(8):1427-32.

7.
8.

Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.

Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y.

Am J Kidney Dis. 1998 Aug;32(2):238-46.

PMID:
9708607
9.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
10.

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.

Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48-54.

PMID:
9808143
11.

Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.

Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.

J Nephrol. 2009 Jan-Feb;22(1):59-68.

PMID:
19229819
12.

Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.

Cozzolino M, Galassi A, Gallieni M, Brancaccio D.

Curr Vasc Pharmacol. 2008 Apr;6(2):148-53. Review.

PMID:
18393917
13.

A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.

Tarrass F, Yazidi A, Sif H, Zamd M, Benghanem MG, Ramdani B.

Clin Nephrol. 2006 Jun;65(6):415-8.

PMID:
16792136
14.

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.

Am J Kidney Dis. 2007 Jun;49(6):814-23.

PMID:
17533024
15.

A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.

Lindberg J, Martin KJ, González EA, Acchiardo SR, Valdin JR, Soltanek C.

Clin Nephrol. 2001 Oct;56(4):315-23.

PMID:
11680662
16.

Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.

Alghareeb A, Sabry A, Bawadekji H, Alsaran K.

Ther Apher Dial. 2013 Feb;17(1):30-4. doi: 10.1111/j.1744-9987.2012.01131.x. Epub 2012 Oct 30.

PMID:
23379490
17.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
18.

Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.

Gu Y, Ding F, Chen N, Mei CL, Qian JQ, Wang XY, Shi W, Hou FF, Li XW, Wang M, Chen YP.

Ren Fail. 2005;27(2):205-12. Erratum in: Ren Fail. 2005;27(6):805. Ding, Feng [added]; Chen, Nan [added]; Mei, Chang-lin [added]; Qian, Jia-qi [added]; Wang, Xiao-yun [added]; Shi, Wei [added]; Hou, Fan-fan [added]; Li, Xue-wang [added]; Wang, Mei [added]; Chen, Yi-pu [added].

PMID:
15807187
19.

Efficacy of intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis.

González MT, Torregrosa JV, Colomé E, Mendia A, Pavesi M.

Nephron Clin Pract. 2008;108(2):c141-7. doi: 10.1159/000115326. Epub 2008 Feb 6.

PMID:
18259100
20.

[Prevalence and quality of control of calcium and phosphorus metabolism disorders among Lithuanian hemodialysis patients in 2004 and 2005].

Petrauskiene V, Ziginskiene E, Kuzminskis V, Burciuviene A, Grazulis S, Sileikiene E, Masalskiene J, Juodeikiene L, Tamosaitis D, Alisauskiene V.

Medicina (Kaunas). 2007;43 Suppl 1:58-64. Lithuanian.

Supplemental Content

Support Center